Metabolism and Diabetes

Metabolism and Diabetes

A growing epidemic

Type 2 diabetes is a global public health crisis that threatens the economies of all nations, particularly developing countries. Fuelled by rapid urbanisation, nutrition transition, and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity.

Peptide platform

ImmuPharma’s subsidiary ‘Ureka’ has initiated the development of a novel and innovative Urelix peptide technology platform through the collaboration with CNRS, which has the ability to mimic protein structures, allowing for the preservation (or enhancement) of function while significantly increasing protein stability.


The first therapeutic area being targeted is diabetes with glucagon-like peptide -1 agonists, a class of drugs for the treatment of diabetes, as well as initiating the development of novel peptides as glucagon antagonists – one of the novel approaches to treat Type I and Type II diabetes.

Pre-clinical work

Earlier stage pre-clinical work is on-going using the same approach in peptide modification with the first indication in non-alcoholic steatohepatitis (NASH), a severe type of Non-alcoholic fatty liver disease (NAFLD).

The potential of this technology is substantial and diverse and is one of the key reasons UREKA has established its own research team.

To contact us click here